LTS Lohmann Therapie-Systeme AG — Cyborg Score 7/10
Strong
Pharmaceutical Drug Delivery Systems
Strategic Profile
LTS focuses on two core technologies—transdermal therapeutic systems (TTS) and oral thin films (OTF)—while expanding into innovative microneedle and active LTS TTS technology. The company operates state-of-the-art GMP-compliant manufacturing facilities in West Caldwell, NJ and Andernach, Germany, positioning it as a critical partner in pharmaceutical development and manufacturing.
Cyborg Score Rationale
Market leadership position in transdermal and oral film delivery systems reflects operational excellence and client trust. November 2025 acquisition by Renaissance Lakewood indicates strong valuation and ongoing private equity interest. Limited public data on recent financial performance constrains the score.
Top Insights
Market leader position in transdermal therapeutic systems and oral thin films—a specialized niche with high barriers to entry
November 2025 buyout by Renaissance Lakewood positions company for potential operational optimization and scale expansion
Active R&D pipeline includes microneedle technology and active LTS TTS innovations, addressing next-generation drug delivery
Dual-continent manufacturing footprint (US and Germany) provides geographic diversification and supply chain resilience
Named Competitors
Transdermal Patches — Transdermal drug delivery systems
Oral Thin Films — Oral thin film technology and manufacturing
Drug Delivery Systems — Transdermal therapeutic systems
Recent Developments
(November 2025) Acquired by Renaissance Lakewood in leveraged buyout transaction
(2026) Continues partnerships with pharmaceutical manufacturers on transdermal and oral thin film development
Open the full interactive LTS Lohmann Therapie-Systeme AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.